Apple (NASDAQ:AAPL) Shares Gain 3.5% as Market Focuses on Low-Capex Strategy Ahead of Earnings

Apple (NASDAQ:AAPL) Shares Gain 3.5% as Market Focuses on Low-Capex Strategy Ahead of Earnings

NEW YORK, July 25, 2026, 14:10 EDT

  • Apple finished Friday at $333.02, gaining 3.53%. The Nasdaq dropped 0.64%.
  • Apple reported free cash flow of $78.3 billion over the last six months. In comparison, Alphabet Inc. posted $4.3 billion during the same period.
  • Analysts surveyed by Visible Alpha project quarterly revenue of $108.1 billion. Apple is scheduled to announce results on Thursday.

Apple Inc. rose 3.53% on Friday, closing at $333.02. The Nasdaq Composite dropped 0.64%. U.S. markets did not open on Saturday.

The surge boosted market value by about $167 billion at current capitalization. Despite this, Apple finished the week down 0.2%.

This outperformed the Nasdaq’s 2.0% decline for the week. Technology stocks slid as investors evaluated the increasing costs associated with artificial-intelligence infrastructure.

Shares of Alphabet Inc. dropped 7% on Thursday as the company increased its planned expenditures and disclosed a negative free cash flow for the quarter.

Apple’s strong performance on Friday indicates that investors might be distinguishing between AI involvement and capital requirements. Company filings provide supporting evidence.

Both companies reported comparable operating cash flow over their most recent half-year periods. However, their post-capex outcomes diverged significantly.

Latest reported six-month periodApple, ended March 28Alphabet, ended June 30
Total revenue$254.94 billion$229.69 billion
Operating cash flow$82.63 billion$84.86 billion
Capital spending$4.34 billion$80.60 billion
Free cash flow*$78.28 billion$4.26 billion
Capital expenditure as percentage of revenue1.7%35.1%

Free cash flow is defined as operating cash flow minus capital expenditure. Reporting periods vary; ratios derive from company disclosures.

Apple turned 94.7% of its operating cash into free cash flow, while Alphabet achieved a 5.0% conversion rate.

Alphabet’s capital expenditures represented 35.1% of its revenue, while Apple’s figure stood at 1.7%. This drove a free-cash-flow difference between the two of 18.4 times.

Peter Andersen, chief executive of Andersen Capital Management, referred to what he called a “fear of massive overbuilding.” Reuters

Apple’s challenge now is growth. Visible Alpha’s initial consensus expects revenue for the fiscal third quarter to reach $108.1 billion, reflecting a 15.0% increase from the prior year.

Initial figures show iPhone sales reached $53.0 billion, a rise of 18.9%. Services revenue is projected at $31.4 billion, marking a 14.5% increase. The gross margin for Services stands at over 70%.

The combination is able to fuel cash production without the need for hyperscale capital expenditures. Still, shares ended Friday just 1.2% under Visible Alpha’s $337 price target. The consensus multiple for 2027 stands at 34 times earnings.

Apple is scheduled to report results Thursday at 5 p.m. EDT. The Federal Reserve is set to meet on Tuesday and Wednesday. As of late Friday, futures indicated a 38% probability of a 25-basis-point rate hike.

Risks: The analysis relies on varying fiscal periods and omits non-capex expenses for AI. Early estimates may turn out elevated. An unexpected move by the Fed might weigh on Apple’s premium valuation.

Apple stands out now for its capital efficiency rather than for having a low stock price. On Thursday, it must demonstrate that minimal infrastructure costs can still drive robust growth.

Leokadia Głogulska is a financial and technology journalist at TS2.tech, covering stocks, artificial intelligence, space technology and global market developments. She graduated from Wrocław University of Economics and Business and previously worked in financial analysis before moving into business journalism. Her reporting focuses on helping readers understand the market trends, companies and technologies shaping the global economy.

Stock Market Today

  • Revolution Medicines (RVMD) Shares Trade at a Premium Despite Robust Gains
    July 25, 2026, 2:47 PM EDT. Revolution Medicines (RVMD) shares have jumped with a 399.2% return over the past year and approximately 6.4x growth in three years, though the stock's valuation is considered steep. With a P/B ratio of 26.8x, Revolution Medicines is well above the Biotech sector's 2.5x average and peer level of 10.3x. The stock meets just 2 out of 6 valuation criteria, indicating a premium linked to its FDA-reviewed drug daraxonrasib and data from its pancreatic cancer trial, along with concerns tied to regulatory risk.
Marvell Technology, Inc. (NASDAQ:MRVL) Gains in Premarket as AI Ambitions Face High Expectations
Previous Story

Marvell Technology (NASDAQ:MRVL) Rises Over Week Even After 7% Friday Drop